title: Mechanisms of isoniazid resistance in Mycobacterium tuberculosis.
abstract: Isoniazid (INH) is a widely used front-line antituberculous agent with bacteriocidal activity at concentrations as low as 150 nM against Mycobacterium tuberculosis. INH is a prodrug and requires activation by an endogenous mycobacterial enzyme, the catalase-peroxidase KatG, before exerting toxic effects on cellular targets. Resistance to INH develops primarily through failure to activate the prodrug due to point mutations in the katG gene. In addition to mutations in katG, mutations in several other loci, such as the alkylhydroperoxidase AhpC and the enoylreductase InhA, may contribute to INH resistance. Although these markers can be used to accurately predict clinical INH resistance in a large number of cases, the molecular mechanisms involved remain largely speculative and incomplete.
authors.affiliation: Tuberculosis Research Unit, Rocky Mountain Laboratories, National Institutes for Allergy and Infectious Disease, National Institutes of Health, Hamilton, Montana 59840, USA. clifton_barry@nih.gov
authors.forename: C E
authors.initials: CE
authors.lastname: Barry
authors.forename: R A
authors.initials: RA
authors.lastname: Slayden
authors.forename: K
authors.initials: K
authors.lastname: Mdluli